June 16 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Friday it has advised manufacturers that are updating their COVID-19 vaccines to develop monovalent shots to target the XBB.1.5 subvariant.

Source: https://www.marketscreener.com/quote/stock/NOVAVAX-INC-58256108/news/US-FDA-advises-COVID-vaccine-makers-to-develop-shots-aimed-at-XBB-1-5-variant-44133502/?utm_medium=RSS&utm_content=20230616

My first question also get to 154, given that the Meiji and the CSL, I believe has a deal signed earlier this year, my question is, does CSL also have the rights outside of United – outside of Japan for the monovalent vaccine?

Source: https://seekingalpha.com/article/4602294-arcturus-therapeutics-holdings-inc-arct-q1-2023-earnings-call-transcript?source=feed_all_articles

People aged five years and above who wish to receive the updated Pfizer-BioNTech/Comirnaty monovalent vaccine may do so from Oct 30. The vaccine will be available to children aged six months to four years from Nov 20.

Source: https://www.channelnewsasia.com/singapore/covid-19-updated-vaccine-singapore-new-dose-pfizer-moderna-3879716?cid=cna_flip_070214